lutetium has been researched along with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid) in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, S; Chakraborty, S; Das, T; Pillai, MR; Samuel, G; Sarma, HD; Unni, PR; Venkatesh, M | 1 |
| Chakraborty, S; Chakravarty, R; Dash, A; Kamaleshwaran, K; Radhakrishnan, E; Rajeswari, A; Sarma, HD; Shinto, AS; Vimalnath, KV | 1 |
| Arani, SS; Maraghe, MG; Mehrabi, M; Salek, N; Samani, AB; Vosoghi, S | 1 |
3 other study(ies) available for lutetium and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)
| Article | Year |
|---|---|
177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.
Topics: Animals; Bone Neoplasms; Heterocyclic Compounds, 1-Ring; Lutetium; Organophosphonates; Organophosphorus Compounds; Pain; Palliative Care; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Tissue Distribution | 2002 |
A "mix-and-use" approach for formulation of human clinical doses of
Topics: Animals; Bone Neoplasms; Cancer Pain; Durapatite; Humans; Lutetium; Male; Organophosphorus Compounds; Pharmacy Service, Hospital; Radioisotopes; Rats; Tissue Distribution | 2017 |
Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation.
Topics: Ablation Techniques; Animals; Bone Marrow; Femur; Lutetium; Mice; Models, Biological; Organophosphorus Compounds; Radiation Dosage; Radioisotopes; Rats, Wistar; Samarium; Tissue Distribution; Yttrium Radioisotopes | 2018 |